Q3
CCEL — Q3 2026 Financial Report Analysis
Cryo-Cell fiscal Q3 2026: revenue flat at $7.82M as new cord blood enrollments fell 16%, but net income rose 70% to $1.27M ($0.16/share) on lower costs, investment gains, lower interest and a lower tax rate; Duke arbitration ruling pending.